10.2 Expedited Reporting and the Sponsor Awareness Clock

Expedited Reporting and the Sponsor Awareness Clock

A Suspected Unexpected Serious Adverse Reaction (SUSAR) represents the highest tier of urgent safety concern in clinical drug development. A safety event qualifies as a SUSAR only when it satisfies all three of the following independent criteria simultaneously:

1. Serious: The event meets at least one of the six regulatory seriousness criteria (results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, causes persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event).

2. Suspected Related (Adverse Reaction): There is at least a "reasonable possibility" of a causal relationship between the investigational product and the adverse event, as assessed by either the Principal Investigator or the sponsor.

3. Unexpected: The nature, severity, specificity, or outcome of the reaction is not consistent with the applicable Reference Safety Information (RSI) located in the Investigator's Brochure or approved package insert.

Why SUSARs Demand Expedited Action

SUSARs represent critical changes in the known benefit-risk balance of an investigational medicinal product (IMP). Because the reaction was not previously anticipated in the Investigator's Brochure, neither the regulatory authorities, the Institutional Review Boards / Independent Ethics Committees (IRBs/IECs), nor the participating trial subjects were informed of this potential hazard during trial approval and informed consent. Consequently, health authorities require rapid, expedited reporting so they can evaluate whether other ongoing studies using the same molecule must be paused, amended, or terminated.

Expedited Regulatory Reporting Timelines: ICH E2A

The International Council for Harmonisation guideline ICH E2A establishes globally accepted expedited reporting timeframes. These standards are codified into national regulations, including US FDA 21 CFR 312.32 and European Union guidelines.

The Fatal or Life-Threatening Timeline: The "7 + 8 Calendar Day Rule"

When an unexpected adverse reaction results in death or is immediately life-threatening, the regulatory reporting clock accelerates:

• Initial Expedited Notification (Within 7 Calendar Days):
  • The sponsor must notify regulatory authorities (e.g., FDA, EMA, PMDA) as soon as possible, and no later than 7 calendar days after initial receipt of the qualifying information by the sponsor.
  • This initial report may be preliminary (via electronic submission or secure safety portal), but must contain minimum essential reporting details.
• Complete Written Follow-up Report (Within an Additional 8 Calendar Days):
  • The sponsor must submit as complete a follow-up report as possible within an additional 8 calendar days following the initial 7-day notification (often referenced as Day 7 + 8 = 15 calendar days total from original awareness).
  • The follow-up report should include available follow-up and an assessment of the finding's significance; actively seek missing information.

All Other Serious, Unexpected Reactions: The "15 Calendar Day Rule"

For all other serious, unexpected reactions that are neither fatal nor immediately life-threatening (e.g., resulting in initial or prolonged inpatient hospitalization, persistent disability, congenital anomaly, or requiring medical intervention):

• Comprehensive Written Report (Within 15 Calendar Days):
  • The sponsor must file an initial safety report with the minimum information, followed by updates to regulatory authorities as soon as possible, and no later than 15 calendar days after initial receipt of the qualifying information.

The "Day 0" Concept: Clock Start Criteria

The reporting clock starts on Day 0—defined as the exact calendar day when the sponsor (or any individual, affiliate, or Contract Research Organization [CRO] acting on the sponsor's behalf) first receives or becomes aware of the four minimum reporting criteria:

1. An Identifiable Patient: (e.g., subject identification number, initials, age, or sex).
2. An Identifiable Reporter: (e.g., investigator name, site staff title, or clinic address).
3. An Identifiable Investigational Product: (e.g., study drug name, protocol code).
4. An Adverse Event Outcome Meeting Criteria: (a serious, unexpected adverse event with suspected relationship).

Once these four elements exist in the sponsor's possession, Day 0 is established. The sponsor cannot delay the start of the reporting clock while waiting for complete medical records or hospital discharge summaries.

Site-to-Sponsor Reporting Requirements: ICH E6(R3)

While sponsors bear the legal obligation to report to regulatory authorities, investigative sites are the frontline source of all clinical safety data.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1, ICH E2A, WMA Declaration of Helsinki, 2024.